-+ 0.00%
-+ 0.00%
-+ 0.00%

InMed FY26 net loss widens to US$12.9 million; discontinued-ops sales drop 36% to US$3.2 million

PUBT·09/09/2026 20:31:38
Listen to the news
InMed FY26 net loss widens to US$12.9 million; discontinued-ops sales drop 36% to US$3.2 million
  • InMed Pharmaceuticals posted a net loss attributable to common shareholders of USD 12.99 million, widening from USD 8.16 million.
  • Operating expenses climbed to USD 11.61 million from USD 8.47 million, including R&D of USD 3.03 million and G&A of USD 6.66 million.
  • Cash, cash equivalents and short-term investments fell to USD 2.23 million from USD 10.79 million.
  • BayMedica discontinued operations recorded sales of USD 3.2 million, down from USD 5 million.
  • Merger with Mentari remains targeted for Q4 2026, with expected aggregate pre-closing financing of about USD 490 million and a planned CVR for legacy assets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609091630NEWSFILECNPR____20260909_313685_1) on September 09, 2026, and is solely responsible for the information contained therein.